Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Orexo AB ( (SE:ORX) ) has provided an announcement.
Orexo reported weak first-quarter 2026 financials from its continued operations, with net revenues falling to SEK 5 million and posting a wider net loss, while operating expenses remained heavily weighted toward research and development. The company also executed an early redemption of its SEK 500 million senior secured social bond, which, together with existing cash, is intended to ensure sufficient capacity to advance its pipeline following the divestment of its Zubsolv U.S. business.
Operationally, Orexo moved several pipeline assets toward value-inflection milestones, including continued stability work on opioid-overdose rescue drug Izipry ahead of a planned FDA resubmission, accelerated commercial-scale readiness for anaphylaxis treatment OX640, and completion of a first in-vivo study for adulterated-overdose candidate OX390. The company also broadened its AmorphOX-based semaglutide program into oral tablet formulations and filed a related patent, underlining a strategic focus on maintaining a central role from development to commercialization in programs with significant long-term potential.
More about Orexo AB
Orexo AB is a Sweden-based specialty pharmaceutical company focused on developing and commercializing drug delivery technologies, particularly nasal formulations for acute and specialty care indications. Its key pipeline products include Izipry for opioid overdose, OX640 for severe allergic reactions such as anaphylaxis, and OX390 for adulterated overdoses, all leveraging its proprietary AmorphOX platform and targeting high-need emergency treatment markets.
Average Trading Volume: 45,846
Technical Sentiment Signal: Sell
Current Market Cap: SEK705.4M
For an in-depth examination of ORX stock, go to TipRanks’ Overview page.